Boo-boos be gone with Smith & Nephew’s No-Sting Skin-Prep spray
ST. PETERSBURG, Fla. Smith & Nephew has created a liquid film-forming dressing that dries in less than 30 seconds.
The company’s alcohol-free No-Sting Skin-Prep spray has a four-day wear time and leaves a clear, waterproof, breathable and conformable barrier that allows for visual assessment of the periwound area.
"Our new No-Sting Skin-Prep spray enhances patient comfort because it is conformable, protects the skin from incontinence and friction, and won’t irritate damaged skin," said Tom Dugan, president of the North American wound management divsion at Smith & Nephew. "For the caregiver, the fast-drying spray offers quick and easy application, and long-lasting products save time and money. No-Sting Skin-Prep spray can help protect vulnerable skin, reducing the risk of costly infections. The addition of No-Sting Skin-Prep spray to our liquid film-forming dressing line and our broad portfolio of trusted wound care brands reflects our commitment to providing solutions that promote positive patient outcomes and cost-effective patient care."
Endo boosts portfolio with Qualitest acquisition
CHADDS FORD, Pa. Endo Pharmaceuticals will acquire generic drug maker Qualitest Pharmaceuticals for $1.2 billion, Endo said Tuesday.
Endo said the purchase of privately owned Qualitest would expand its offering of branded drugs, generics, devices and services in areas such as pain and urology. Qualitest is the sixth largest generic drug company in the United States, as measured by prescriptions filled.
“This is an exciting day for Endo,” Endo president and CEO David Holveck said. “The acquisition of Qualitest accelerates our stated strategy of building a diversified healthcare company better able to respond to the changing economics that drive the U.S. healthcare environment.”
Sun Pharma gets FDA approval for ALS generic
MUMBAI, India The Food and Drug Administration has approved a generic version of a drug for a devastating muscular disorder.
Sun Pharmaceutical Industries announced Tuesday the approval of riluzole hydrochloride in the 50-mg strength. The tablets are used to treat amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig’s disease.
The drug is a generic version of Sanofi-Aventis’ Rilutek, which has sales of around $50 million, according to Sun.